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Background. Morbidity, severity, and mortality associated with annual influenza epidemics are of public health concern. We 
analyzed surveillance data on hospitalized laboratory-confirmed influenza cases admitted to intensive care units to identify common 
determinants for fatal outcome and inform and target public health prevention strategies, including risk communication.
Methods. We performed a descriptive analysis and used Poisson regression models with robust variance to estimate the asso-
ciation of age, sex, virus (sub)type, and underlying medical condition with fatal outcome using European Union data from 2009 to 
2017.
Results. Of 13 368 cases included in the basic dataset, 2806 (21%) were fatal. Age ≥40 years and infection with influenza A virus 
were associated with fatal outcome. Of 5886 cases with known underlying medical conditions and virus A subtype included in a 
more detailed analysis, 1349 (23%) were fatal. Influenza virus A(H1N1)pdm09 or A(H3N2) infection, age ≥60 years, cancer, human 
immunodeficiency virus infection and/or other immune deficiency, and heart, kidney, and liver disease were associated with fatal 
outcome; the risk of death was lower for patients with chronic lung disease and for pregnant women.
Conclusions. This study re-emphasises the importance of preventing influenza in the elderly and tailoring strategies to risk 
groups with underlying medical conditions.
Keywords: age; EU; influenza virus; intensive care units; underlying medical conditions.
Influenza viruses pose a permanent threat to public health due 
to seasonal epidemics with surges of associated morbidity and 
mortality and their pandemic potential [1–5]. Therefore, in-
tense global surveillance is conducted to constantly monitor 
and assess the epidemiological and virological situation and 
evaluate prevention and control measures [6–8]. The World 
Health Organization underlines the need to specifically monitor 
severe disease and its clinical patterns, causative viral strains, 
and population groups at risk [9]. The severity and impact of 
annual influenza epidemics are key indicators for assessing 
both seasonal and pandemic situations, particularly indicators 
based on influenza-related hospitalizations and deaths. These 
data are used to inform stakeholders, prioritize and allocate re-
sources, and target prevention strategies to the most vulnerable. 
Vaccination programs in particular depend on the identifica-
tion of specific risk groups [10].
Many studies performed during and after the 2009 influ-
enza pandemic have described risk factors in the context of an 
influenza pandemic or seasonal epidemics, but they used dif-
ferent study populations and different end points, eg, disease 
progression, hospitalization, intensive care unit (ICU) admis-
sion, or death [11–13]. Previously identified risk factors include 
increasing age, cardiovascular disease, malignancy, immuno-
suppression, hypertension, neuromuscular disease, diabetes 
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mellitus, chronic lung, liver, or metabolic renal disease [14, 15]. 
Obesity and pregnancy were associated with increased risk of 
severe outcomes in some but not all studies [15–18]. According 
to European data, infection with influenza virus A(H1N1)
pdm09, older age, immunosuppression, pregnancy, and lung or 
heart disease are associated with increased risk of fatal outcome 
of influenza [11, 16].
The European Centre for Disease Prevention and Control 
(ECDC) has conducted hospital-based surveillance of se-
vere influenza since the pandemic in 2009 [19]. Aggregate 
data are published weekly during the influenza season [6], but 
case-based data have not been systematically analyzed at the 
European level [20, 21]. Therefore, our aim was to analyze data 
on laboratory-confirmed influenza cases admitted to ICUs to 
identify common determinants of fatal outcome that may in-
form risk communication and help target prevention strategies.
METHODS
Data Source
During each influenza surveillance season, ECDC collects 
weekly case-based data on hospitalized laboratory-confirmed 
influenza cases admitted to ICU from a number of European 
Union (EU)/European Economic Area (EEA) Member States 
[22, 23]. The data for the seasons 2009–2010 to 2016–2017 
(weeks 40–20) were retrieved from the European Surveillance 
System (TESSy) database. A  description of the surveil-
lance systems in the countries reporting data is available at 
FluNewsEurope webpage [24].
Data Set
Reported information on laboratory-confirmed cases in ICUs 
included the following: influenza virus type; subtype (A(H1N1)
pdm09, A(H3N2)) and lineage (B/Victoria, B/Yamagata); age 
(year); sex; duration of hospitalization (time between admission 
to hospital and either discharge or death); complications (acute 
respiratory distress syndrome [ARDS], bronchitis, encephalitis, 
myocarditis, pneumonia, sepsis, other); vaccination status (not 
vaccinated, pandemic, seasonal, or both vaccines); date of vac-
cination; respiratory support (not required, ventilation or ox-
ygen support); and outcome (deceased or alive). Due to limited 
data reported on B-lineage, specific analysis in relation to B 
lineages was not feasible. The following underlying conditions 
were reported: asthma, cancer, chronic heart, kidney, liver or 
lung disease, diabetes, human immunodeficiency virus (HIV)/
other immune deficiency, neurocognitive and neuromuscular 
disorders, pregnancy, obesity, and morbid obesity. Countries 
were also able to report additional other underlying conditions 
in a free text field, and those covered a mix of various different 
genetic and acquired conditions as well as infectious diseases 
such as tuberculosis, hepatitis B or C, etc. Asthma and lung dis-
ease were pooled as chronic lung condition. Morbid obesity and 
obesity were pooled because analyzing them separately did not 
show any differences. Information about the date of vaccination 
and vaccine type was very limited. A full overview of reported 
data by country is available in Supplementary Tables.
Data Analysis
A basic dataset was compiled to analyze the relationship be-
tween age, sex, virus type, and fatal outcome. Inclusion criteria 
were as follows: laboratory-confirmed influenza cases admitted 
to ICU, influenza virus type A or B confirmation, known age, 
sex, and outcome (Basic dataset) (Figure 1).
Underlying medical conditions and A  virus subtypes were 
only available for a subset of cases within the basic dataset but 
were considered important factors for analysis. Therefore, we 
created a subset of the basic dataset that included cases with 
known influenza A  virus subtype (or B type) and underlying 
condition(s) (Specific dataset) (Figure 1).
Additional variables analyzed independently were dura-
tion of hospitalization, complications, vaccination status, and 
respiratory support. Because these additional variables were 
only incompletely reported, they were not included in any 
multivariable analysis because they would have substantially 
reduced the number of eligible cases. For the analysis of preg-
nancy, the analysis was restricted to women 17–50 years of age 
adjusting for the reporting country.
We performed a descriptive analysis of the pooled data 
across seasons and reporting countries. Descriptive statistics in-
cluded absolute and relative frequencies of each study variable. 
Continuous variables were compared by using Wilcoxon rank-
sum test, Mann-Whitney test, and Student’s t test. We applied 
different statistical models according to Barros et  al [25] as a 
sensitivity analysis to identify the best possible method. Poisson 
regression models with robust variance were applied to identify 
statistically significant determinants of fatal outcome. The use 
of robust variance intended to improve the variance estimation 
to adjust for dispersion of the data by reducing the effect of out-
liers. Crude and adjusted risk ratios (incidence rate ratio [IRR]) 
and 95% confidence intervals (CIs) were determined. The re-
porting country was included in the final model to adjust for 
country effects. A  second model was developed based on the 
subset of the basic dataset that included cases with known un-
derlying conditions and influenza A  virus subtype (A(H3N2) 
or A(H1N1)pdm09) or B type. The significance level was set at 
0.05. Stata 14 (StataCorp) was used for the statistical analysis.
RESULTS
Descriptive Analysis
The inclusion criteria for the basic dataset were met by 13 368 
cases reported from 12 countries during the study period 2009–
2010 to 2016–2017 (Figure 1). The number of reporting coun-
tries varied each season with France and Spain reporting the 
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majority of cases (57% and 26%, respectively). Of the 13  368 
patients in ICU with laboratory-confirmed influenza virus in-
fection, 2806 (21%) died (Table 1). The majority of cases were 
male (7604; 57%). The median age was 59 years (interquartile 
range, ±14 years; range, 0–104 years). Most of the cases (7566; 
57%) were between 50 and 79 years of age, and 10% of the cases 
were 18 years old or younger.
Most influenza viruses (11 809; 88%) were type A: 5223 (44%) 
were subtyped as A(H1N1)pdm09, 1975 (17%) were subtyped 
as A(H3N2), and 4611 (39%) were reported without subtype. 
In all seasons, there were more influenza A  viruses (>60% of 
viruses) compared with B viruses among ICU cases. In seasons 
with higher proportions of A(H3N2) detections, the propor-
tion of unsubtyped A viruses was also higher than in seasons 
with A(H1N1)pdm09 dominance. The proportion of influenza 
B virus cases was greater than 20% in both the 2012/2013 and 
2015/2016 season. The highest proportion of B viruses (20%) 
was observed in those aged less than 20 years.
Duration of Hospitalization
The duration of hospitalization was available for 952 cases (7%) 
whose median stay was 10  days (range, 0–198  days) and did 
not significantly differ between influenza virus types (P =  .1). 
However, the median stay of cases who recovered was signifi-
cantly longer than in fatal cases (13 vs 10 days; P = .003).
Underlying Conditions and Virus Type/Subtype
Among 5886 cases with known influenza virus type and A sub-
type (A(H1N1)pdm09 and A(H3N2)) and underlying condi-
tions (Specific dataset) (Figure 1), 23% percent (1349) died 
(Table 1). More cases were male (3205; 54%) than female. 
A total of 2552 cases (43%) were reported to have no underlying 
condition. One condition was reported for 2498 (42%) cases, 2 
conditions were reported for 569 cases (10%), 3 conditions were 
reported for 198 cases (3%), and 4 to 6 conditions were reported 
for less than 2% of the patients. The most commonly reported 
underlying conditions were chronic lung disease (18%) and 
obesity (15%). Influenza virus A(H1N1)pdm09 was detected in 
the majority (3512; 60%) of the patients, followed by A(H3N2) 
(1286; 22%) and type B (1088; 18%).
Respiratory Support
Data about respiratory support were available for 8667 (65%) 
of the 13  368 patients. Support was not required for 1005 
(12%) patients, oxygen was given to 506 (6%) patients, and 
7156 (83%) patients were ventilated. Of 579 patients reported 
to have pneumonia, 430 (74%) were ventilated, 118 (20%) re-
ceived oxygen, and 31 (5%) received no respiratory support. 
Of 3085 patients with ARDS, 2843 (92%) were ventilated, 134 
(4%) were reported to be given oxygen, and 108 (3.5%) received 
no respiratory support. The risk of death increased more than 
4-fold when ventilation had to be commenced (IRR, 3.98; 95% 
CI, 3.03–5.23), but not for patients only given oxygen support 
(IRR, 1.02; 95% CI, 0.68–1.52) compared with patients without 
any respiratory support, adjusting for reporting country, age, 
and sex.
Complications
Data about complications during the course of disease 
were available for 7592 (57%) cases. The most commonly 
reported complications were ARDS (51%) and pneumonia 
(41%). Acute respiratory distress syndrome (IRR, 1.02; 95% 
CI, 0.92–1.13), encephalitis (IRR, 1.16; 95% CI, 0.78–1.70), 
and pneumonia (IRR, 0.91; 95% CI, 0.82–1.02) were not 
associated with an increased risk of death adjusting for re-
porting country, age, and sex. Although sepsis and myocar-
ditis were reported only for 6% and less than 2% of the 7592 
cases, respectively, both were associated with increased risk 
of death (sepsis: IRR, 2.65; 95% CI, 2.41–2.90; myocarditis: 
IRR, 1.30; 95% CI, 1.00–1.67).
Patients admitted to ICU with laboratory-confirmed influenza virus infection
2009/10–2016/17 (weeks 40–20)
N = 21 216
Influenza virus A subtype determined
N = 8757
Known underlying conditions
N = 5886
Known age and gender
N = 14 227
Known outcome
N = 13 368
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Figure 1. Flow chart of cases included in the analysis. ICU, intensive care unit.
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/6/11/ofz462/5608594 by guest on 08 M
ay 2020
4 • ofid • Adlhoch et al
Vaccination
Vaccination status was known for 9215 (69%) of the 13  368 
cases, with 2162 (23%) reported as having been vaccinated with 
either seasonal (2011 cases), pandemic (42), or both vaccines 
(109). The median duration of hospitalization did not differ be-
tween vaccinated and nonvaccinated patients (10.5 vs 10 days). 
Vaccination was preventive for fatal outcome (IRR, 0.86; 95% 
CI, 0.78–0.95) adjusting for reporting country, virus type, age, 
and sex.
Information on vaccination and underlying conditions were 
only provided for a limited number of cases (6052). In addition, 
information on date of vaccination was only available for 40 of 
all cases, and for 28 of them the date of onset of disease was pro-
vided in addition with a range of 0–185 days between vaccina-
tion and disease onset. Therefore, reporting on vaccination was 
considered biased and not included in the overall multivariable 
analysis.
Pregnancy
Pregnancy was reported for 244 women between 17 and 
59 years of age. Twenty-four (10%) of the pregnant women died. 
Of the 153 pregnant women with known vaccination status, 3 
were vaccinated and 150 were unvaccinated. The risk of death 
was lower for pregnant women when restricting the analysis 
to the age group 17–50 years old compared with nonpregnant 
women of the same age group (IRR, 0.57; 95% CI, 0.38–0.85) 
and adjusting for reporting country within the basic dataset. 
No difference was seen between France reporting the majority 
of cases and other countries as well as between pandemic and 
nonpandemic seasons (Supplementary Data).
Within the specific dataset when restricting the analysis to 
women 17–50  years old and adjusting for reporting country, 
pregnant women were less likely to die (IRR, 0.63; 95% CI, 
0.41–0.96). Underlying conditions such as HIV/immunosup-
pression (IRR, 2.11; 95% CI, 1.48–3.03) or heart disease (IRR, 
1.81; 95% CI, 1.12–2.91) increased the risk to die.
Univariable and Multivariable Analysis
In the basic model including cases with known gender, age, and 
influenza virus type, the determinants associated with fatal out-
come in the univariable analysis were male sex, age of 40 years 
and older, and infection with influenza A virus (Table 1). The 
risk for fatal outcome increased by 1.5% with each year of age 
(IRR, 1.02; 95% CI, 1.01–1.02), using age as continuous vari-
able. In the multivariable model, influenza A  virus infection 
and older age (≥40  years) were significantly associated with 
mortality. The highest risk ratio was identified in people of 
80 years of age and older.
The univariable analysis of cases with detailed information 
about influenza A  virus subtype and underlying conditions 
again identified being male and 40 years or older as determin-
ants of fatal outcome (Table 2). Cancer, heart, liver, and kidney 
disease, HIV infection/other immune deficiencies as well as 
other underlying conditions were identified as risk factors for 
fatal outcome, whereas patients of younger age and with chronic 
lung disease were less likely to die. In the multivariable model, 
age 60 years and older, cancer, chronic heart, kidney, and liver 
disease, as well as HIV infection/other immune deficiency and 
other underlying conditions were confirmed as determinants 
of fatal outcome. In addition, infection either with A(H1N1)
pdm09 or A(H3N2) virus was retained.
DISCUSSION
This is the first published analysis of confirmed influenza ICU 
cases reported from 12 EU countries over 8 consecutive sea-
sons. Confining the analysis to ICU cases was intended to im-
prove data comparability across countries, although criteria 
for ICU admission might not have been uniform across coun-
tries and hospitals. We confirmed several known determinants 
contributing to a greater risk of fatal outcome. In addition, the 
association between sepsis as a clinical complication and an 
increased risk of death underlines the clinical impact of early 
treatment and care in these severely ill patients. No informa-
tion was available on why some patients admitted to ICU did 
not receive respiratory support, ie, the information was missing 
or not reported: either such patients had been transferred to 
ICU for precautionary reasons, there was missing case informa-
tion, or data were not reported. In addition, no information on 
timing of complications in relation to ICU admission was avail-
able within this dataset as well as on other complications such as 
secondary bacterial infections or related treatment.
The present study is limited by the small number of EU coun-
tries reporting. Cases were reported from only 12 of the 31 EU/
EEA Member States, and so their cases might not be representa-
tive of all severe cases across the EU/EEA. A further limitation 
of this study is the differences in ICU reporting systems between 
Member States and the pooling of such case-based data across 
countries that have different underlying healthcare systems and 
surveillance [26]. The imbalance between the contributions of 
the various countries over time might also limit the comparability 
of the data. Nevertheless, we assessed the variation by applying 
different statistical methods and identified a reasonable test to 
compensate for the reporting country effect according to Barros 
et al [25]; however, different underlying data collection cannot be 
solved by pure statistics. We believe that this study, even with its 
limitations, provides valuable information on several determin-
ants relevant for increased risk of fatal outcome due to influenza 
in Europe. The identified limitations of reporting and pooling of 
such case-based clinical data across countries will need to be ad-
dressed to develop more robust variables and apply clinical se-
verity scores. This process needs to create data independent from 
the respective underlying surveillance system to be useful to 
identify determinants for severe disease and fatal outcome.
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Table 1. Risk Factors for Fatal Outcome in Laboratory-Confirmed Influenza Cases in ICU, 12 EU/EEA Countries, 2009/10–2016/17, Basic Dataset
Determinants
Recovered 
Cases  
N = 10 562
Fatal Cases  
N = 2 806 Univariable Analysis  Multivariable Analysis
n % n % Risk Ratio (95% CI) P Value
Adjusteda  
Risk Ratio (95% CI) P Value
Gender
 Female 4603 44 1161 41 Ref.   Ref.  
 Male 5959 56 1645 59 1.08 (1.01–1.15) .030 1.05 (0.98–1.12) .143
Age in Years
 0–19 1191 11 123 4.4 0.59 (0.48–0.72) <.001 0.60 (0.49–0.74) <.001
 20–39 1274 12 233 8.3 Ref.   Ref.   
 40–59 3278 31 787 28.1 1.27 (1.12–1.45) <.001 1.26 (1.10–1.44) .001
 60–79 3777 36 1289 45.9 1.70 (1.50–1.93) <.001 1.70 (1.50–1.93) <.001
 80+ 1042 10 374 13.3 1.87 (1.61–2.16) <.001 1.87 (1.61–2.16) <.001
Virus Type
 A 9249 88 2560 91 1.37 (1.21–1.54) <.001 1.31 (1.16–1.47) <.001
 B 1313 12 246 9 Ref.      
Significant findings (p < 0.05) in bold.
Abbreviations: CI, confidence interval; EEA, European Economic Area; EU, European Union; ICU, intensive care unit; Ref., Reference.
aAdjusted for reporting country.
Table 2. Risk Factors for Fatal Outcome in Laboratory-Confirmed Influenza Cases in ICU, 12 EU/EEA Countries, 2009/10–2016/17, Specific Dataset
Determinants
Recovered 
Cases 
N = 4 537
Fatal Cases 
N = 1 349 Univariable Analysis Multivariable Analysis
n % n % Risk Ratio (95% CI) P Value
Adjusteda Risk Ratio 
(95% CI) P Value
Gender
 Female 2113 47 586 42 Ref.   Ref.  
 Male 2424 53 781 58 1.15 (1.05–1.26) .003 1.12 (1.02–1.23) .019
Age in Years
 0–19 504 11 60 5 0.59 (0.44–0.78) <.001 0.66 (0.50–0.87) .003
 20–39 645 14 137 10 Ref.    Ref.  
 40–59 1439 32 421 31 1.29 (1.09–1.53) .003 1.23 (1.04–1.46) .013
 60–79 1547 34 581 43 1.62 (1.37–1.90) <.001 1.71 (1.45–2.02) <.001
 80+ 402 9 150 11 1.68 (1.37–2.05) <.001 2.00 (1.61–2.47) <.001
Underlying Conditions
 Cancer 92 2 74 6 2.22 (1.83–2.70) <.001 1.84 (1.51–2.23) <.001
 Diabetes 371 8 154 11 1.08 (0.94–1.26) .284 b   
 Heart disease 418 9 230 17 1.32 (1.16–1.51) <.001 1.19 (1.04–1.37) .012
 HIV/Immune deficiency 169 4 146 11 1.80 (1.58–2.07) <.001 1.67 (1.45–1.91) <.001
 Kidney disease 106 2 86 6 1.71 (1.45–2.02) <.001 1.38 (1.16–1.64) <.001
 Liver disease 114 3 67 5 1.42 (1.17–1.73) <.001 1.29 (1.06–1.57) .013
 Chronic lung infection 651 14 222 17 0.86 (0.76–0.97) .016 0.82 (0.73–0.93) .002
 Neurocognitive 45 1 14 1 1.05 (0.67–1.65) .819 b   
 Neuromuscular disorders 88 2 29 2 0.97 (0.71–1.33) .872 b   
 Obesity 673 15 211 16 1.05 (0.92–1.19) .690 1.05 (0.92–1.20) .486
 Other 110 2 49 4 1.32 (1.03–1.69) .031 1.32 (1.02–1.71) .037
Virus Subtype
 B 912 20 176 13 Ref.   Ref.   
 A(H1N1)pdm09 2632 58 880 65 1.52 (1.31–1.76) <.001 1.56 (1.35–1.82) <.001
 A(H3N2) 993 22 293 22 1.31 (1.10–1.55) .002 1.19 (1.00–1.41) .047
Significant findings (p < 0.05) in bold.
Abbreviations: CI, confidence interval; EEA, European Economic Area; EU, European Union; HIV, human immunodeficiency virus; ICU, intensive care unit; Ref., Reference.
aAdjusted for reporting country and pregnancy.
bNot included in the final mode.
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The proportion of fatal cases among patients in ICU was higher 
in this study (21%) than in previous analyses (mean 16%) [11, 27], 
which might be due to the inclusion criteria we used: known virus 
type, age, gender, and outcome. The results showed an increasing 
risk of death associated with influenza A and increasing age over 
40 years, which partly confirms the findings of other studies that 
indicate mortality during A(H3N2) seasons mostly affects people 
65  years of age and older and middle-aged during A(H1N1)
pdm09-dominated seasons [28, 29]. However, fatality in ICU 
represents only a small fraction of the mortality toll of influenza, 
particularly in the elderly, which are less likely to be admitted to 
ICU and have also been shown to be less likely tested for influenza 
virus infection in the hospital setting [30].
The data reported to TESSy were not complete regarding 
influenza virus A  subtype and B lineage as well as under-
lying conditions. A considerable number of cases (4611; 34%) 
from the basic dataset had to be dropped from the specific 
subset analysis due to missing virus subtype information. The 
high proportion of unsubtyped influenza A  viruses, ranging 
from 0.1% during the pandemic season 2009/2010 to 60% in 
2016/2017, limited determination of the dominant virus sub-
type for most of the seasons in the analysis. We also observed 
that the proportion of unsubtyped influenza A  viruses was 
higher in A(H3N2)-predominant seasons than in A(H1N1)
pdm09 seasons. This might be explained by the fact that detec-
tion systems specifically developed for A(H1N1)pdm09 during 
the 2009 pandemic continue to be used in diagnostics, so if in-
fluenza A viruses test negative in the specific A(H1N1)pdm09 
test, they are reported as “influenza A unsubtyped”, which cre-
ates a bias towards more A(H1N1)pdm09 cases in the subtype-
specific analyses. Another reason could be an increased testing 
for influenza A  and B in acute hospital settings using point-
of-care tests without further subtyping. Better virological data 
would be desirable for a better assessment of the clinical im-
pact of the virus subtype but also regarding vaccine effective-
ness. In a French study, female sex and influenza vaccination 
were described as protective factors with regard to ARDS in se-
verely ill patients [16]. In our study, vaccination showed some 
protection; however, the data on vaccination status had several 
limitations in the available information on vaccination date, 
vaccine type, and onset of disease. The small number of cases 
with information on underlying conditions and vaccination 
status did not allow for a more in-depth analysis.
Our analysis supports previous findings that HIV infection/
other immune deficiency, cancer, heart, kidney, and liver disease 
increase the likelihood of fatal outcomes as do increasing age 
over 40 years and influenza A infection [14, 15, 31]. All EU/EEA 
Member States recommend annual influenza vaccination for per-
sons 65 years of age and older. Recommendations for persons with 
the following chronic medical conditions vary across countries: 
respiratory (pulmonary), cardiovascular, chronic neurological, he-
patic and renal disease, immunosuppression, metabolic disorders, 
HIV/acquired immune deficiency syndrome, and morbid obesity 
[32, 33]. Our analysis showed that HIV infection/other immu-
nosuppressive disorders are associated with an increased risk of 
death; however, no specific information on “other immune defi-
ciencies” was provided. People with HIV infection are known to 
be at greater risk of dying from influenza and its complications due 
to their susceptibility to infection, and they are specifically targeted 
by Member State vaccination programs [10, 34–36]. With the con-
stant number of approximately 30 000 newly diagnosed HIV in-
fections each year and over 500 000 estimated people with HIV 
in EU/EEA countries, influenza vaccines as well as early antiviral 
treatment should be offered to them as a priority group [37–39].
Others identified an association between pre-existing lung, neu-
romuscular or neurocognitive disease, or obesity and fatal outcome 
in hospitalized patients; however, this was not seen among ICU pa-
tients in this analysis [14, 15]. In our study, chronic lung condition 
including asthma was not associated with an increased risk of death 
in line with a recent meta-analysis [31]. A previous study described 
an association of earlier hospital admission and less severe outcomes 
in asthmatics compared with nonasthmatics [40]. Pregnancy is con-
sidered a risk factor for severe influenza [11], and a large majority 
of EU/EEA Member States recommended influenza vaccination 
for pregnant women [32, 33]. Although approximately 3% of all 
our cases were pregnant women, our findings did not show any in-
creased risk for fatal outcome when admitted to ICU and confirm 
findings of others [15, 31]. Pregnancy, chronic lung disease, and 
obesity may increase the risk for hospitalization and ICU admission, 
rather than fatal outcome. It can be speculated that early hospitaliza-
tion, early onset of treatment, and transfer to ICU as a precaution in 
these patients’ populations may prevent severe disease progression. 
The earlier identification of these conditions as risk factors might 
have contributed to increased awareness and better clinical care 
preventing fatal outcomes.
CONCLUSIONS
This study highlights the importance of preventing influenza virus 
infection, particularly in the elderly, but also in tailoring strategies 
to protect risk groups with underlying conditions, which includes 
the use of antiviral treatment and vaccination [41].
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